Healthcare companies by risk reading
Healthcare companies by risk reading: 1,695 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 21 October 2026.
Composite readings for 14,899 companies, recomputed 21 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| InnoCare Pharma Limited 9969.HK | 18 | Contained | Healthcare | China | 5 / 6 | $2.8B |
| Soleno Therapeutics Inc SLNO | 36 | Normal | Healthcare | United States | 4 / 6 | $2.8B |
| Medacta Group SA MOVE.SW | 39 | Normal | Healthcare | Switzerland | 5 / 6 | $2.7B |
| Acadia Healthcare Company Inc ACHC | 63 | Stretched | Healthcare | United States | 4 / 6 | $2.7B |
| Nurix Therapeutics Inc NRIX | 35 | Normal | Healthcare | United States | 5 / 6 | $2.7B |
| Aveanna Healthcare Holdings Inc AVAH | 60 | Stretched | Healthcare | United States | 4 / 6 | $2.7B |
| Sundrug Co.,Ltd. 9989.T | 44 | Elevated | Healthcare | Japan | 5 / 6 | $2.7B |
| ATAI Life Sciences N.V. ATAI | 59 | Elevated | Healthcare | United States | 4 / 6 | $2.7B |
| Zai Lab Ltd ZLAB | 36 | Normal | Healthcare | China | 6 / 6 | $2.7B |
| Alfresa Holdings Corporation 2784.T | 48 | Elevated | Healthcare | Japan | 5 / 6 | $2.6B |
| BioArctic AB (publ) BIOA-B | 53 | Elevated | Healthcare | Sweden | 3 / 6 | $2.6B |
| Kusuri No Aoki Holdings Co., Ltd. 3549.T | 41 | Elevated | Healthcare | Japan | 5 / 6 | $2.6B |
| Guardian Pharmacy Services Inc GRDN | 31 | Normal | Healthcare | United States | 5 / 6 | $2.5B |
| Neogen Corp NEOG | 49 | Elevated | Healthcare | United States | 5 / 6 | $2.5B |
| Beam Therapeutics Inc BEAM | 36 | Normal | Healthcare | United States | 5 / 6 | $2.5B |
| Adma Biologics Inc ADMA | 39 | Normal | Healthcare | United States | 6 / 6 | $2.5B |
| Almirall, S.A. ALM.MC | 50 | Elevated | Healthcare | Spain | 3 / 6 | $2.5B |
| Transmedics Group Inc TMDX | 24 | Normal | Healthcare | United States | 5 / 6 | $2.5B |
| HUTCHMED (China) Ltd HCM | 57 | Elevated | Healthcare | Hong Kong | 5 / 6 | $2.4B |
| EBOS Group Limited EBO.AX | 52 | Elevated | Healthcare | Australia | 4 / 6 | $2.4B |
| NewAmsterdam Pharma Company NV NAMS | 70 | Stretched | Healthcare | Netherlands | 5 / 6 | $2.4B |
| Precigen Inc PGEN | 81 | Acute | Healthcare | United States | 4 / 6 | $2.4B |
| Bausch Health Companies Inc BHC | 57 | Elevated | Healthcare | Canada | 5 / 6 | $2.4B |
| Viridian Therapeutics Inc VRDN | 54 | Elevated | Healthcare | United States | 4 / 6 | $2.4B |
| GN Store Nord GN | 59 | Elevated | Healthcare | Denmark | 3 / 6 | $2.4B |
| Prestige Consumer Healthcare Inc PBH | 49 | Elevated | Healthcare | United States | 5 / 6 | $2.4B |
| Brookdale Senior Living Inc BKD | 69 | Stretched | Healthcare | United States | 5 / 6 | $2.4B |
| Celldex Therapeutics Inc CLDX | 75 | Stretched | Healthcare | United States | 6 / 6 | $2.3B |
| Supernus Pharmaceuticals Inc SUPN | 53 | Elevated | Healthcare | United States | 5 / 6 | $2.3B |
| EBOS Group Limited EJG | 54 | Elevated | Healthcare | Australia | 4 / 6 | $2.3B |
| Suzuken Co., Ltd. 9987.T | 56 | Elevated | Healthcare | Japan | 4 / 6 | $2.3B |
| AddLife AB (publ) ALIF-B | 48 | Elevated | Healthcare | Sweden | 4 / 6 | $2.3B |
| UFP Technologies Inc UFPT | 36 | Normal | Healthcare | United States | 6 / 6 | $2.3B |
| HUTCHMED (CHINA) LS-1 H7T2 | 46 | Elevated | Healthcare | Hong Kong | 5 / 6 | $2.2B |
| Haw Par Corporation Limited H02.SI | 27 | Normal | Healthcare | Singapore | 5 / 6 | $2.2B |
| Perrigo Company plc PRGO | 63 | Stretched | Healthcare | Ireland | 5 / 6 | $2.2B |
| Day One Biopharmaceuticals Inc DAWN | 45 | Elevated | Healthcare | United States | 5 / 6 | $2.2B |
| Pediatrix Medical Group Inc MD | 40 | Elevated | Healthcare | United States | 5 / 6 | $2.2B |
| Aurinia Pharmaceuticals Inc AUPH | 43 | Elevated | Healthcare | Canada | 6 / 6 | $2.2B |
| Harmony Biosciences Holdings Inc HRMY | 34 | Normal | Healthcare | United States | 6 / 6 | $2.2B |
| Shanghai Conant Optical Co., Ltd. 2276.HK | 28 | Normal | Healthcare | China | 5 / 6 | $2.2B |
| Progyny Inc PGNY | 42 | Elevated | Healthcare | United States | 3 / 6 | $2.2B |
| Addus HomeCare Corporation ADUS | 29 | Normal | Healthcare | United States | 6 / 6 | $2.2B |
| FORTE SOFTWARE INC FTRE | 81 | Acute | Healthcare | United States | 4 / 6 | $2.1B |
| Shanghai Junshi Biosciences Co., Ltd. 1877.HK | 52 | Elevated | Healthcare | China | 5 / 6 | $2.1B |
| Avadel Pharmaceuticals plc AVDL | 58 | Elevated | Healthcare | Ireland | 4 / 6 | $2.1B |
| Neogenomics Inc NEO | 63 | Stretched | Healthcare | United States | 5 / 6 | $2.1B |
| Agios Pharmaceuticals Inc AGIO | 49 | Elevated | Healthcare | United States | 6 / 6 | $2.1B |
| Vericel Corp VCEL | 28 | Normal | Healthcare | United States | 6 / 6 | $2.1B |
| Biocryst Pharmaceuticals Inc BCRX | 16 | Contained | Healthcare | United States | 5 / 6 | $2.1B |
| Grand Pharmaceutical Group Limited 0512.HK | 49 | Elevated | Healthcare | Hong Kong | 5 / 6 | $2.0B |
| Select Medical Holdings Corporation SEM | 47 | Elevated | Healthcare | United States | 5 / 6 | $2.0B |
| Inspire Medical Systems Inc INSP | 46 | Elevated | Healthcare | United States | 6 / 6 | $2.0B |
| SKAN Group AG SKAN | 43 | Elevated | Healthcare | Switzerland | 5 / 6 | $2.0B |
| Duality Biotherapeutics, Inc. 9606.HK | 44 | Elevated | Healthcare | China | 5 / 6 | $2.0B |
| Trulieve Cannabis Corp. TRLV | 41 | Elevated | Healthcare | United States | 5 / 6 | $2.0B |
| GeneDx Holdings Corp - Class A WGS | 42 | Elevated | Healthcare | United States | 6 / 6 | $2.0B |
| Butterfly Network Inc - Class A BFLY | 51 | Elevated | Healthcare | United States | 6 / 6 | $2.0B |
| Grifols SA GRFS | 45 | Elevated | Healthcare | Spain | 5 / 6 | $2.0B |
| LAKEFRONT BIOTHER. LKFT.AS | 33 | Normal | Healthcare | Belgium | 6 / 6 | $1.9B |
| Recursion Pharmaceuticals Inc - Class A RXRX | 67 | Stretched | Healthcare | United States | 6 / 6 | $1.9B |
| Surgery Partners Inc SGRY | 42 | Elevated | Healthcare | United States | 5 / 6 | $1.9B |
| Shandong Weigao Group Medical Polymer Company Limited 1066.HK | 49 | Elevated | Healthcare | China | 5 / 6 | $1.9B |
| Immunome Inc IMNM | 61 | Stretched | Healthcare | United States | 4 / 6 | $1.9B |
| Xeris Biopharma Holdings Inc XERS | 30 | Normal | Healthcare | United States | 5 / 6 | $1.9B |
| Genus plc GNS.L | 44 | Elevated | Healthcare | United Kingdom | 4 / 6 | $1.9B |
| Axogen Inc AXGN | 66 | Stretched | Healthcare | United States | 6 / 6 | $1.9B |
| Biolife Solutions Inc BLFS | 44 | Elevated | Healthcare | United States | 5 / 6 | $1.9B |
| ADARx Pharmaceuticals, Inc. ADRX | 43 | Elevated | Healthcare | United States | 4 / 6 | $1.9B |
| Lemaitre Vascular Inc LMAT | 33 | Normal | Healthcare | United States | 6 / 6 | $1.9B |
| Sarepta Therapeutics Inc SRPT | 50 | Elevated | Healthcare | United States | 5 / 6 | $1.9B |
| Fagron NV FAGR | 32 | Normal | Healthcare | Belgium | 5 / 6 | $1.9B |
| Fukuda Denshi Co., Ltd. 6960.T | 37 | Normal | Healthcare | Japan | 5 / 6 | $1.9B |
| Zymeworks BC Inc ZYME | 65 | Stretched | Healthcare | United States | 4 / 6 | $1.8B |
| Attendo ATT.ST | 33 | Normal | Healthcare | Sweden | 3 / 6 | $1.8B |
| Galapagos NV GLPG | 16 | Contained | Healthcare | Belgium | 5 / 6 | $1.8B |
| The United Laboratories International Holdings Limited 3933.HK | 45 | Elevated | Healthcare | Hong Kong | 5 / 6 | $1.8B |
| Alamar Biosciences, Inc. ALMR | 59 | Elevated | Healthcare | United States | 5 / 6 | $1.8B |
| Dynavax Technologies Corp DVAX | 50 | Elevated | Healthcare | United States | 5 / 6 | $1.8B |
| EMEIS SA EMEIS | 49 | Elevated | Healthcare | France | 5 / 6 | $1.8B |
| Apollo Medical Holdings Inc ASTH | 42 | Elevated | Healthcare | United States | 5 / 6 | $1.8B |
| Tsumura & Co. 4540.T | 37 | Normal | Healthcare | Japan | 5 / 6 | $1.8B |
| ProBiotix Health Plc PBX.AQ | 43 | Elevated | Healthcare | United Kingdom | 3 / 6 | $1.8B |
| Qilian International Holding Group Ltd - Class A BGM | 83 | Acute | Healthcare | China | 4 / 6 | $1.8B |
| Metis TechBio Co., Ltd. 7666.HK | 42 | Elevated | Healthcare | China | 5 / 6 | $1.8B |
| Alvotech ALVO | 40 | Elevated | Healthcare | Luxembourg | 5 / 6 | $1.8B |
| Neuren Pharmaceuticals Limited NEU.AX | 20 | Normal | Healthcare | Australia | 3 / 6 | $1.8B |
| Novavax Inc NVAX | 44 | Elevated | Healthcare | United States | 5 / 6 | $1.8B |
| PolyPeptide Group AG PPGN | 55 | Elevated | Healthcare | Switzerland | 5 / 6 | $1.8B |
| LWB1 LWB1 | 45 | Elevated | Healthcare | Australia | 5 / 6 | $1.8B |
| Angelalign Technology Inc. 6699.HK | 31 | Normal | Healthcare | China | 5 / 6 | $1.7B |
| Kestra Medical Technologies Ltd KMTS | 45 | Elevated | Healthcare | United States | 5 / 6 | $1.7B |
| Establishment Labs Holdings Inc ESTA | 60 | Stretched | Healthcare | United States | 6 / 6 | $1.7B |
| NovoCure Ltd NVCR | 65 | Stretched | Healthcare | Switzerland | 6 / 6 | $1.7B |
| Schrodinger Inc SDGR | 43 | Elevated | Healthcare | United States | 6 / 6 | $1.7B |
| Vir Biotechnology Inc VIR | 70 | Stretched | Healthcare | United States | 6 / 6 | $1.7B |
| Embla Medical hf EMBLA | 47 | Elevated | Healthcare | Iceland | 3 / 6 | $1.7B |
| Xencor Inc XNCR | 72 | Stretched | Healthcare | United States | 5 / 6 | $1.7B |
| Faes Farma SA FAE | 42 | Elevated | Healthcare | Spain | 5 / 6 | $1.7B |
| Vigonvita Life Sciences Co., Ltd. 2630.HK | 79 | Stretched | Healthcare | China | 4 / 6 | $1.7B |
By sector
Industrials 3,117Technology 2,425Consumer Cyclical 2,231Healthcare 1,695Consumer Defensive 1,055Basic Materials 1,055Real Estate 1,011Communication Services 956Energy 487Utilities 343Financial Services 90
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.